A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 01 Oct 2015
At a glance
- Drugs LOP 628 (Primary)
- Indications Acute myeloid leukaemia; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 28 Sep 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 12 Mar 2015 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.
- 15 Jan 2015 Planned End Date changed from 1 Nov 2017 to 1 Jun 2020 as reported by ClinicalTrials.gov record.